Company’s next chapter centers on advancing its innovative clinical-stage development pipeline 
 

NASHVILLE, Tenn. (Sept. 14, 2026) – Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, today outlined the next stage of its evolution following a major strategic transition, designed to sharpen the Company’s focus on advancing new therapies for significant unmet medical needs.

Cumberland Pharmaceuticals CEO A.J. Kazimi discussed the Company’s new direction during Nashville Health Care Council's annual Sessions Conference. The transition positions Cumberland to concentrate its resources and expertise on advancing its clinical-stage development portfolio while continuing to support Nashville’s growing healthcare and life sciences ecosystem.

“This is a defining moment for Cumberland and an important step in our evolution,” said Kazimi. “With a more focused strategy and a promising pipeline, we are well positioned to build on our experience developing and delivering differentiated medicines. Just as importantly, Cumberland remains firmly committed to leading the growth of the life sciences segment of Nashville’s nation leading healthcare industry, and to helping strengthen the community that has supported our Company from its beginnings here.”

Cumberland’s development efforts are led by ifetroban, a first-in-class oral therapy being evaluated across several indications. Cumberland’s late stage clinical programs are designed to address conditions in which patients continue to face significant unmet needs, including the cardiomyopathy associated with Duchenne muscular dystrophy-associated, systemic sclerosis and idiopathic pulmonary fibrosis.

Cumberland will also maintain its investment in Cumberland Emerging Technologies (CET), founded in collaboration with Vanderbilt University and Launch Tennessee. CET is working with researchers at Vanderbilt and other academic centers to identify their scientific breakthroughs that have commercial potential, and advancing them towards the market. CET also manages Nashville’s Life Sciences Center, which houses Cumberland’s formulation laboratories and provides research facilities, office space, business resources and a collaborative environment for other emerging life sciences companies.

“Nashville has become one of the country’s most dynamic healthcare markets, and we are proud to have built Cumberland here,” Kazimi added. “As we enter this next chapter, we plan to continue investing in the people, partnerships and scientific community here that make this an exceptional place to grow life sciences companies and develop new medicines for the future.”

Cumberland’s strategic transformation follows the company’s recent transaction involving the divestment of its portfolio of commercial pharmaceutical brands. The transaction  provided  significant financial resources to support Cumberland’s ongoing clinical development programs and pursue opportunities aligned with its long-term focus on delivering innovative biopharmaceutical products.

About Cumberland Pharmaceuticals 

Cumberland Pharmaceuticals Inc. is an innovation-driven biopharmaceutical company developing new therapies to address significant unmet medical needs and improve the quality of patient care. The Company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs.

Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis. 
For more information, please visit www.cumberlandpharma.com.

Forward-Looking Statements 

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland’s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company’s intent, belief or expectations, and can be identified by the use of terminology such as “may,” “will,” “expect,” “believe,” “intend,” “plan,” “estimate,” “goal,” “should,” “seek,” “anticipate,” “look forward” and other comparable terms or the negative thereof. As with any business, all phases of Cumberland’s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland’s results of operations. These factors include risks and uncertainties related to the Company’s strategic transaction, risks related to its ability to successfully develop and register its pipeline of new product candidates, the risks inherent in clinical development, regulatory review, macroeconomic conditions, including changes in interest rates, inflation, tariffs, competition and other events beyond the Company’s control as more fully discussed in its most recent quarterly report on Form 10-Q as filed with the U.S. Securities and Exchange Commission (“SEC”), as well as the Company’s other filings with the SEC from time to time. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

SOURCE: Cumberland Pharmaceuticals Inc.

                                                                ###